Sign In
Buy SHIEF
$0.0800
+0 (+0%)
At Close: Jun 02, 2026
Shield Therapeutics on track after strong quarter as it looks to raise $10m in new investment
05:33am, Tuesday, 29'th Oct 2024
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) reported strong sales for the third quarter of 2024. It unveiled plans to raise around $10 million of new investment and reiterated its aim of becoming c
Shield Therapeutics shares up 8% after phase III success
03:29am, Wednesday, 25'th Sep 2024
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF)'s share price rose 8% following the announcement of successful phase III trial results for its iron deficiency treatment, Accrufer, which could pave the
Shield Therapeutics hails paediatric phase III study success
02:40am, Wednesday, 25'th Sep 2024
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF), a UK-based pharmaceutical company specialising in treatments for iron deficiency, announced on Wednesday successful results from a pivotal phase III cli
Shield Therapeutics is enjoying significant growth for its iron deficiency product - ICYMI
06:26am, Saturday, 07'th Sep 2024
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) interim CEO Anders Lundstrom and CFO Santosh Shanbhag talked with Proactive about the company's impressive growth in the iron deficiency market. They di
Shield Therapeutics growth 'encouraging', says broker
07:08am, Thursday, 05'th Sep 2024
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) progress was lauded by Peel Hunt in research that followed the speciality pharma group's interims on Wednesday. "We continue to think the current underl
Shield Therapeutics a strong period of revenue growth as prescription numbers grow
03:05am, Wednesday, 04'th Sep 2024
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) hailed another 'strong period of growth' as it delivered a more than three-fold increase in revenue in the first half based on the growing uptake of its
Shield Therapeutics shares up 7% after Canada green light
04:44am, Tuesday, 27'th Aug 2024
Shares in Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) rose 7% in early trading following the approval of its drug, Accrufer (ferric maltol), by Health Canada for treating iron deficiency anaemia
Shield Therapeutics announces approval of ACCRUFeR in Canada
02:27am, Tuesday, 27'th Aug 2024
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) has announced that Health Canada has approved ACCRUFeR (ferric maltol) as a prescription drug for the treatment of adults with iron deficiency anaemia (I
Shield Therapeutics CEO steps down
02:54am, Wednesday, 24'th Jul 2024
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) said that chief executive Greg Madison is stepping down from the role by mutual consent to pursue other opportunities, leaving the company immediately.
Shield Therapeutics 'fortifies' balance sheet with $5.7m monetisation deal
08:47am, Wednesday, 03'rd Jul 2024
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF), the commercial-stage pharma company, has entered into a $5.7 million monetisation agreement with AOP Health International Management, its biggest shareh
Shield Therapeutics shares up 7% after $5.7m monetisation deal
08:47am, Wednesday, 03'rd Jul 2024
Shares in Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) were almost 7% higher in afternoon trading after the commercial-stage pharma group 'fortified' its balance sheet with a $5.7m monetisation deal
Shield Therapeutics 'fortifies' balance sheet with $5.7m monetisation deal with biggest shareholder
02:48am, Wednesday, 03'rd Jul 2024
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF), the commercial-stage pharma company, has entered into a $5.7 million monetisation agreement with AOP Health International Management, its biggest shareh
Shield Therapeutics may receive forecast update following Accrufer application, says broker
07:50am, Tuesday, 28'th May 2024
Broker Peel Hunt has kept its rating on Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) under review following news that its Korean partner has filed a new drug application for Accrufer. This filing co
Shield Therapeutics files for South Korean regulatory approval for Accrufer
02:57am, Tuesday, 28'th May 2024
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF)'s partner, Korea Pharma, has filed a New Drug Application (NDA) for Accrufer with the country's Ministry of Food and Drug Safety. This filing is a cruc
Peel Hunt to update Shield Therapeutics' forecast model
06:56am, Monday, 13'th May 2024
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF)'s full-year results, where the company reported a trebling of total revenues, were consistent with a recent first-quarter business update, said broker Pe
